Linked Life Data

20700780

Source:http://linkedlifedata.com/resource/pubmed/id/20700780

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2010-8-11
pubmed:abstractText
Targeted drugs that modulate the function of specific molecules in diseased tissues hold great promise for the treatment of many diseases, including malignant tumors. However, there are several challenges for the efficient evaluation of these drugs in clinical trials as well as for the use in clinical practice. These include (i) the selection of patients likely to benefit from treatment with a specific targeted drug, (ii) finding the right dose and dose schedule, (iii) monitoring target inhibition, and (iv) assessing tumor response to therapy. Standard anatomic imaging continues to play an important role for addressing these challenges, but molecular imaging provides several new opportunities to make the use of targeted drugs more efficient. Using molecular imaging, the expression of drug targets can be assessed noninvasively, the concentration of drugs can be measured in the tumor tissue, target inhibition can be monitored, and tumor response to therapy can be evaluated earlier than with anatomic imaging techniques. Therefore, it is expected that molecular imaging will play an increasing role for guiding molecularly defined therapeutic interventions.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1437-1588
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
810-7
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Molecular imaging in cancer therapy].
pubmed:affiliation
Nuklearmedizinische Klinik, Universitätsklinikum Freiburg, Deutschland. wolfgang.weber@uniklinik-freiburg.de
pubmed:publicationType
Journal Article, English Abstract, Review